Retatrutide FAQ: common questions answered

An experimental weekly injection with phase 3 weight-loss results.

Also called: LY3437943, LY-3437943, Reta.

GLP-1 / GIP / glucagon agonists · GIP, GLP-1 and glucagon receptor triple agonist.

  • Is Retatrutide FDA-approved? Not FDA-approved. The sponsor reports phase 3 completion and plans a Q1 2027 submission; NCT07629401 provides pre-approval expanded access.
  • How do people take it? Under the skin, once weekly. 48 weeks. Source: studied in a trial.
  • What's the difference between Retatrutide and Tirzepatide? Retatrutide: an experimental weekly injection with phase 3 weight-loss results. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: users seek appetite control or switch drugs. No human trial tested combined use.
  • Can I take it with Tirzepatide? Users seek appetite control or switch drugs. No human trial tested combined use. Tirzepatide's label advises against other GLP-1 drugs. Poor intake, vomiting and blood sugar changes may worsen. Source: reported by users. Ask a doctor before combining anything.
  • Is it banned in sport? It is unclear (WADA 2026). Australia’s 2026 page says retatrutide is not listed and GLP-1 drugs are not banned. WADA S0 broadly covers unapproved drugs; a specific ruling is needed.
  • How long does a mixed vial last? Users report 2–8°C refrigeration; shelf life in bacteriostatic water is unknown. FDA’s general 28-day limit after first use of sterile vials does not establish these products’ stability or sterility.

Related to Retatrutide

Sources

Sources checked: 2026-10-22.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.